Background: Despite available evidence that implantable cardioverter defibrillators (ICDs) reduce all-cause mortality among patients at risk for sudden cardiac death, utilization of ICDs is low especially in developing countries.
INTRODUCTION
Evidence from multiple randomized clinical trials have demonstrated the effectiveness of implantable cardioverter defibrillators (ICDs) in preventing sudden cardiac death (SCD) and lowering mortality in selected patients. 1, 2 ICDs may either be implanted in patients who have previously experienced SCD (secondary prevention [SP]) 3 , or in patients who have not but are at increased risk of experiencing life-threatening ventricular arrhythmias (primary prevention (PP)) 4, 5 .
Despite the evidence, adoption of ICDs remains low in developing countries particularly among PP patients. 6 The reasons for low utilization remain incompletely understood.
Previous studies have shown that certain clinical conditions are correlated with a higher risk for SCD. Syncope presumed cardiac in origin, [7] [8] [9] left ventricular ejection fraction (LVEF) <25%, 10 nonsustained ventricular tachycardia (NSVT), [11] [12] [13] and frequent premature ventricular contraction (PVC), 14, 15 defined as 10 or more PVCs per hour, are associated with a higher mortality rate and an increased risk of ventricular events. Given this, it is plausible that PP patients with one or more of these risk factors may have a risk of ventricular arrhythmias, perhaps closer to that of SP patients. The overall aim of the Improve SCA study is to evaluate whether this subpopulation of PP patients (termed as "1.5 PP patients") has an increased risk of appropriate ICD therapy similar to that of SP patients. This initial report of the Improve SCA study characterizes the 1.5 PP patients enrolled in the trial and reports on the utilization rate of ICDs in developing countries as well as the reasons for implant refusal.
METHODS

Study design
The Improve SCA study is a prospective, nonrandomized, nonblinded, multicenter global study. The details of the study design and 1.5 PP definition have been described previously. 16 In brief, patients were enrolled from geographies where ICD utilization among clinically indicated patients is low (Asia, Latin America, Eastern Europe, the Middle East, and Africa). Patients having a Class I indication for an ICD implantation according to the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) or European Society of Cardiology (ESC) guidelines were approached for participation. 2 After informed consent was signed, patients were categorized as being either PP (defined as patients at The decision to implant an ICD was left to the discretion of the patient and the physician. The reasons for refusal were documented for patients who chose not to undergo implantation. The study was carried out in accordance with the Declaration of Helsinki and the protocol was approved by the Institutional Review Board or Medical Ethics Committee of each study center. All patients provided written informed consent.
Statistical analysis
Continuous data are reported as mean ± standard deviation, and n and % are given for frequency data. Logistic regression was used to analyze factors potentially influencing implant refusal. Only factors with a univariate P value less than 0.25 were included in the multivariable logistic regression model, and no factors were removed from the final model. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used for all analyses.
RESULTS
The Improve SCA study enrolled 4222 patients in 17 countries from March 2014 through July 2017. It was prespecified to exclude patients not meeting important study criteria at baseline from all study analysis, and there were 330 such patients. The majority of reasons for exclusion were inclusion/exclusion criteria violations and not performing 1.5 evaluation per protocol. Among 3892 patients remaining, 2700 were PP and 1192 were SP, respectively. Of the PP patients, 71.0% (n = 1918) were categorized as being 1.5 PP patients.
Baseline characteristics for these groups are shown in Table 1 . Of note, the majority of patients enrolled had non-ischemic cardiomyopathy.
The most common 1.5 risk factor was the presence of frequent PVCs (46.3% of PP patients, Supporting Information Figure S1 ), followed by low LVEF (32.5%), NSVT (30.0%), and syncope (6.2%). Over one-third (34.3%) of PP patients exhibited more than one 1.5 factor with the most common combinations being NSVT and PVC (14.0%); NSVT, PVC, and LVEF (7.4%); and PVC and LVEF (6.8%).
A total of 91 patients did not undergo ICD implantation for reasons beyond the patient's or physician's control (Table 1) . When excluding these patients, the implant refusal rate was 46.5% among PP patients (Table 2 ) with two countries' most common reason for refusal being a reason other than inability to pay: South Korea (unwillingness to pay for the device), and Singapore (not believing in the benefit).
TA B L E 1 Baseline characteristics
Characteristic
Primary prevention (n = 2700), n (%) or mean ± SD Secondary prevention (n = 1192), n (%) or mean ± SD CV = cardiovascular; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; NSVT = nonsustained ventricular tachycardia; PVC = premature ventricular contraction; SD = standard deviation.
Finally, potential baseline characteristics that might influence a patient's implant decision were examined separately for PP and SP patients. For PP patients (Table 3) , the variables that independently had a statistically significant effect on the decision to get an implant included those that demonstrated electrical abnormalities such as atrial arrhythmias, QRS duration, and left bundle branch block (LBBB).
Among the four 1.5 criteria, patients were less likely to refuse in the presence of frequent PVCs, NSVT, or syncope. Country of origin was also a significant factor as seen in Figure 1 .
Modeling for SP patients included different variables (Table 4) because SP patients did not undergo 1.5 testing, and all had a history of ventricular arrhythmias. Only history of previous cardiovascular (CV) surgery (more likely to refuse), and absence of sinus node dysfunction (more likely to refuse), along with country of origin were significant factors in the multivariable analysis.
DISCUSSION
Despite the evidence supporting the use of ICDs in SCD PP, utilization among clinically indicated patients has remained low especially among patients from developing countries. The Improve SCA study was initiated in developing countries as an effort to collect data on CRT-D = cardiac resynchronization therapy defibrillator; ICD = implantable cardioverter defibrillator. Countries with less than five refusals are included in the total, but not included in individual columns.
Most common "other" reasons were: Needs more time to consider (n = 30), feels well and does not want to pursue ICD, 15 fear of device or procedure, 12 lifestyle or occupation will be too affected, 9 feels they are too old for an implant, 7 alternate therapy pursued, 4 and subject wishes to be observed for more time. 4 F I G U R E 1 Patient refusal by prevention type and country. Primary prevention includes 1.5 primary prevention. Red bars represent primary prevention, blue bars represent secondary prevention. y axis is geography and x axis is percentage of patients refusing implantable cardioverter defibrillator implant.
[Color figure can be viewed at wileyonlinelibrary.com]
1.5 PP with the most common finding among 1.5 PP patients being the presence of ventricular arrhythmias; and (3) the most common reason for patients refusing ICDs despite being clinically indicated was being unwilling or unable to pay.
These findings extend observations from a prior study assessing the utilization of ICDs among Asian countries. 6 Among those who refused ICD implantation, the reasons were similar to our findings, with patient unwillingness to pay being the most common followed by a lack of understanding on the benefits and the desire to avoid the risks associated with ICD implantation. Interestingly, our findings differed in the number of individuals refusing therapy. Our study focused primarily on countries where ICD utilization was extremely low (<5%) and included
TA B L E 3
Factors potentially associated with device refusal for primary prevention and 1.5 primary prevention patients 
Country
See Figure 1 n/a n/a <0.0001 n/a n/a <0.0001 may help and with the future availability of the Improve SCA outcomes data, we hope that this will be further evidence in support of the benefits of ICD use among these patients.
Ischemic cardiomyopathy
Limitations
This analysis has several limitations that should be considered when interpreting the results. Many of the patients were enrolled from China, India, South Korea Malaysia, and Singapore; hence, these findings may not accurately represent the characteristics of the other countries participating in this study. Additionally, only a small percentage of centers from each country took part in this study, but every effort was made to select sites that were representative of the overall country makeup. Finally, information on patient outcomes was outside the scope of this manuscript but will be reported in the future as the data become available.
CONCLUSION
Although ICD guideline adherence is suboptimal worldwide, the penetration remains especially low in developing countries. Further patient and physician awareness of SCA risk, along with reform in reimbursement coverage will be important to further bridge the gap between those indicated and those receiving ICD therapy. 
Country
See Figure 1 n/a n/a 0.0001 n/a n/a 0.0001 
Ischemic cardiomyopathy
